BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/22/2022 8:49:02 AM | Browse: 242 | Download: 363
Publication Name World Journal of Clinical Oncology
Manuscript ID 66730
Country/Territory Spain
Received
2021-04-03 23:33
Peer-Review Started
2021-04-03 23:36
To Make the First Decision
Return for Revision
2021-07-06 01:26
Revised
2021-09-04 06:03
Second Decision
2022-04-02 02:09
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2022-04-04 06:10
Articles in Press
2022-04-04 06:10
Publication Fee Transferred
Edit the Manuscript by Language Editor
2022-04-01 03:48
Typeset the Manuscript
2022-04-06 10:21
Publish the Manuscript Online
2022-04-22 08:49
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Minireviews
Article Title Tsunami of immunotherapy reaches mesothelioma
Manuscript Source Invited Manuscript
All Author List Xabier Mielgo-Rubio, Ana Cardeña Gutiérrez, Verónica Sotelo Peña, Maria Virginia Sánchez Becerra, Andrea María González López, Adriana Rosero, Juan Carlos Trujillo-Reyes and Felipe Couñago
ORCID
Author(s) ORCID Number
Xabier Mielgo-Rubio http://orcid.org/0000-0002-0985-6150
Ana Cardeña Gutiérrez http://orcid.org/0000-0001-5972-8651
Verónica Sotelo Peña http://orcid.org/0000-0001-7452-3064
Maria Virginia Sánchez Becerra http://orcid.org/0000-0002-1435-8199
Andrea María González López http://orcid.org/0000-0002-2508-4314
Adriana Rosero http://orcid.org/0000-0002-5144-0757
Juan Carlos Trujillo-Reyes http://orcid.org/0000-0002-3370-0869
Felipe Couñago http://orcid.org/0000-0001-7233-0234
Funding Agency and Grant Number
Corresponding Author Xabier Mielgo-Rubio, MD, Doctor, Staff Physician, Medical Oncology, Hospital Universitario Fundación Alcorcón, Budapest 1, Alcorcón 28922, Madrid, Spain. xmielgo@hotmail.com
Key Words Mesothelioma; Malignant pleural mesothelioma; Immunotherapy; Immune checkpoint inhibitors; Cytotoxic T-lymphocyte–associated antigen 4; Programmed cell death protein 1; Nivolumab; Ipilimumab; Immunotherapy combo; CheckMate 743; CONFIRM
Core Tip Malignant pleural mesothelioma (MPM) is the most common type of malignant mesothelioma and is associated with a poor prognosis. The treatment options for advanced MPM were limited until very recently, when the results from two phase III trials showed improved survival in patients treated with immunotherapy. In the first trial, CheckMate 743, nivolumab plus ipilimumab as first-line therapy achieved better overall survival than standard chemotherapy, while in the second trial, CONFIRM, nivolumab vs placebo significantly improved overall survival in patients previously treated with chemotherapy. In this article, we discuss recent advances and highlights in the treatment of MPM.
Publish Date 2022-04-22 08:49
Citation Mielgo-Rubio X, Cardeña Gutiérrez A, Sotelo Peña V, Sánchez Becerra MV, González López AM, Rosero A, Trujillo-Reyes JC, Couñago F. Tsunami of immunotherapy reaches mesothelioma. World J Clin Oncol 2022; 13(4): 267-275
URL https://www.wjgnet.com/2218-4333/full/v13/i4/267.htm
DOI https://dx.doi.org/10.5306/wjco.v13.i4.267
Full Article (PDF) WJCO-13-267.pdf
Full Article (Word) WJCO-13-267.docx
Manuscript File 66730_Auto_Edited-ZMG-Filipodia CL.docx
Answering Reviewers 66730-Answering reviewers.pdf
Audio Core Tip 66730-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 66730-Conflict-of-interest statement.pdf
Copyright License Agreement 66730-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate 66730-Language certificate.pdf
Peer-review Report 66730-Peer-review(s).pdf
Scientific Misconduct Check 66730-CrossCheck.png
Scientific Misconduct Check 66730-Bing-Gong ZM-2.png
Scientific Editor Work List 66730-Scientific editor work list.pdf